1. In patients with resected stage III mismatch repair-deficient colon cancer, adjuvant atezolizumab plus standard chemotherapy improved disease-free survival compared ...
1. $1.3 billion contract through 2029 makes this one of Samsung BioLogics’ largest agreements. 2. Expansion plans to nearly 1 ...
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
Imfinzi Combo Cuts Gastric Cancer Risk by Twenty Nine Percent Earlier this week at the American Society of Clinical Oncology ...
1. Median overall survival was 3.1 months greater in the nivolumab plus ipilimumab group. 2. Grade 3-4 treatment-related adverse events ...
Imfinzi Combo Shows Promise in Early Gastric Cancer At the American Society of Clinical Oncology meeting earlier this week, investigators ...
1. Patients in the ivonescimab group demonstrated a significantly greater progression-free survival than those in the pembrolizumab group. 2. Grade ...
1. Progression-free survival was significantly greater in the nivolumab plus ipilimumab group compared to nivolumab alone. 2. Treatment-related adverse events ...
1. Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events ...
1. In this phase two dose-finding study in children with achondroplasia, daily oral Infigratinib did not lead to any grade ...
1. Progression-free survival was significantly greater in the lenvatinib plus pembrolizumab group compared to placebo. 2. Overall survival was higher ...
Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.
